Bill · H.R. 1405· House(119-HR-1405)
Enhancing Domestic Drug Manufacturing Competitiveness Act
- Introduced
- 2/18/2025
- Last activity
- 2/18/2025 — Referred to the House Committee on Energy and Commerce.
- Sponsored by
- Vern Buchanan
- Cosponsors
- - 1 - 0
- Introduced
- In Committee
What this bill would do
This bill, known as the "Enhancing Domestic Drug Manufacturing Competitiveness Act," directs the Comptroller General of the United States to conduct a specific study. The goal of this study is to assess regulatory barriers that prevent the expansion or siting of new pharmaceutical manufacturing facilities within the United States. It specifically looks at how these barriers affect the nation's competitiveness compared to other countries. The study will examine the time and cost impacts of these regulations. Additionally, the Comptroller General is tasked with engaging stakeholders to find technological solutions and policy needs. A report containing these findings and recommendations must be submitted to Congress within one year of the Act's enactment.
Yes· 3 of 7
Is this likely to create jobs?+3
The bill seeks to identify ways to expand pharmaceutical manufacturing, which could lead to job growth in that sector.
Would business owners be better off under this?+3
The study aims to identify ways to reduce regulatory costs and time for pharmaceutical manufacturers.
Is this likely to grow the economy?+2
By assessing ways to increase domestic manufacturing competitiveness, the bill aims to support industrial growth.
The opposite
Does this better protect air, water and wildlife?-2
The bill investigates whether existing environmental regulations act as barriers to manufacturing expansion.
Who it would affect, and how
Potential Positive Impacts for People
-
Identification of manufacturing barriers: The study aims to identify regulatory barriers that impede the expansion or siting of new pharmaceutical manufacturing facilities (Section 2(a)(1)). This could help clarify what is stopping growth in the domestic drug manufacturing sector.
-
Assessing competitiveness: The bill directs an assessment of what makes the United States less competitive than other countries for such facilities (Section 2(a)(2)). This could lead to a better understanding of how to keep manufacturing jobs and facilities within the country.
-
Exploring supply chain resiliency: The study will consider the impact of environmental and other regulations on pharmaceutical supply chain resiliency (Section 2(b)(2)). This could help identify ways to make the drug supply more reliable.
-
Seeking technological and policy solutions: The Comptroller General is tasked with identifying promising technological solutions and the policies needed to support them (Section 2(c)(2)-(3)). This could lead to modernizing how drugs are manufactured in the United States.
Potential Negative Impacts for People
- No specific negative impacts are explicitly stated in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Economy And Finance
- Increases Job Creation+3Improves Economic Growth+2
- Demographic And Interest Groups
- Good For Business Owners+3Good For Low Income Households+1
- Healthcare
- Improves Healthcare Access+2Reduces Prescription Drug Costs+2
- Environment Energy And Infrastructure
- Improves Environmental Protections-2
- Governance And Ideology
- Improves Government Transparency+1
- 2/18/2025
- Referred to the House Committee on Energy and Commerce.
- 1 Cosponsor added.
- Introduced in House
Byron DonaldsRepublican · Florida